· 1dBioPharma Dive
FDA clears use of Ozempic to protect kidney health
Novo Nordisk's Ozempic gets FDA approval for kidney disease
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
JD Supra3d
The GLP-1 Saga Continues: FDA Ends the Tirzepatide Shortage: Frequently Asked Questions
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly
Hosted on MSN8d
The FDA is about to make weight-loss drugs a lot harder to get
Eli Lilly and Novo Nordisk, obviously, didn't love the setup, but there wasn't much they could do to stop it, given the shortages. The thing about shortages is that they don't last forever. After some legal wrangling, the FDA pulled tirzepatide from its ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.
A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal?
Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer alternatives to expand the pain management landscape.
AOL13d
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
On Wednesday, the FDA approved Eli Lilly And Co’s (NYSE:LLY) Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its ...
The American Journal of Managed Care5d
FDA Approves Mirikizumab for Crohn Disease
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach to now include the full spectrum of inflammatory bowel disease.
Ibj.com1d
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease and ulcerative colitis, is the company's latest step into the treatment of gastrointestinal diseases.
24/7 Wall St12d
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and currently trading at $756.99. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as effective as bariatric surgery.
MM&M13d
Rx Rundown: Johnson & Johnson, Eli Lilly, the FDA and more
N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form Leo. Synaffix secures ADC deals with Boehringer and Mitsubishi Tanabe.
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. Eli Lilly now expects revenue to be approximately $13.